However, antigen heterogeneity is pronounced in solid tumors including prostate cancer, where progression to mCRPC and treatment resistance are associated with the emergence of divergent disease subtypes marked by distinct transcriptional programs69–71 and cell surface antigen expression17. Here, CD53 is linked to prostate cancer.